Steven Hancock
Publication Details
-
Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol)
J Urol. 1998; (6): 2035-9; discussion 2039-40
Substantial experimental and epidemiological data indicate that 1,25-dihydroxyvitamin D3 (calcitriol) has potent antiproliferative effects on human prostate cancer cells. We performed an open label, nonrandomized pilot trial to determine whether calcitriol therapy is safe and efficacious for early recurrent prostate cancer. Our hypothesis was that calcitriol therapy slows the rate of rise of prostate specific antigen (PSA) compared with the pretreatment rate.
Help